The DOI matches its Crossref record.
Clinical Uses of Melatonin: Evaluation of Human Trials
Abstract
During the last 20 years, numerous clinical trials have examined the therapeutic usefulness of melatonin in different fields of medicine. The objective of this article is to review, in depth, the science regarding clinical trials performed to date. The efficacy of melatonin has been assessed as a treatment of ocular diseases, blood diseases, gastrointestinal tract diseases, cardiovascular diseases, diabetes, rheumatoid arthritis, fibromyalgia, chronic fatigue syndrome, infectious diseases, neurological diseases, sleep disturbances, aging and depression. Melatonin has been also used as a complementary treatment in anaesthesia, hemodialysis, in vitro fertilization and neonatal care. The conclusion of the current review is that the use of melatonin as an adjuvant therapy seems to be well founded for macular degeneration, glaucoma, protection of the gastric mucosa, irritable bowel syndrome, arterial hypertension, diabetes, side effects of chemotherapy and radiation in cancer patients or hemodialysis in patients with renal insufficiency and, especially, for sleep disorders of circadian etiology (jet lag, delayed sleep phase syndrome, sleep deterioration associated with aging, etc.) as well as in those related with neurological degenerative diseases (Alzheimer, etc.,) or Smith-Magenis syndrome. The utility of melatonin in anesthetic procedures has been also confirmed. More clinical studies are required to clarify whether, as the preliminary data suggest, melatonin is useful for treatment of fibromyalgia, chronic fatigue syndrome, infectious diseases, neoplasias or neonatal care. Preliminary data regarding the utility of melatonin in the treatment of ulcerative colitis, Crohns disease, rheumatoid arthritis are either ambiguous or negative. Although in a few cases melatonin seems to aggravate some conditions, the vast majority of studies document the very low toxicity of melatonin over a wide range of doses. Keywords: Melatonin, macular degeneration, glaucoma, gastric mucosa, irritable bowel syndrome, ulcerative colitis, Crohn's disease, rheumatoid arthritis, arterial hypertension, diabetes, fibromyalgia, chronic fatigue syndrome, infectious diseases, neurological diseases, Smith-Magenis syndrome, sleep disturbances, jet lag, shift work, aging, depression, anesthesia, hemodialysis, in vitro fertilization, neonatal care, clinical trials
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many in vitro experiments under different experimental conditions confirmed the good antioxidant activity of melatonin, however, levels of melatonin in certain body organs might not be high enough to exhibit antioxidant properties (Sanchez-Barcelo et al. 2010).”
From Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging (2023) · cites this paper as Sanchez-Barcelo et al. 2010
Citations
Cited by
Sorted by citations
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638
Extrapineal melatonin: sources, regulation, and potential functions
Acuña-Castroviejo, D., Escames, G., Venegas, C., Díaz-Casado, M. E., Lima‐Cabello, E., López, L. C., Rosales‐Corral, S., Tan, D., & Reiter, R. J. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1579-2 · Cited by 1,133
Self-citationMelatonin—A pleiotropic, orchestrating regulator molecule
Hardeland, R., Cardinali, D. P., Srinivasan, V., Spence, D. W., Brown, G. M., & Pandi-Perumal, S. R. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.12.004 · Cited by 843
“Low levels of melatonin were also observed in women with fibromyalgia (Rohr and Herold, 2002; Acuña-Castroviejo et al., 2006; Reiter et al., 2007) and pain has been reported to be reduced by replacement therapy (Citera et al., 2000; Reiter et al., 2007; Sánchez-Barceló et al., 2010).”
BackgroundOn the free radical scavenging activities of melatonin's metabolites, AFMK and AMK
Galano, A., Tan, D. X., & Reiter, R. J. (2012) · Journal of Pineal Research · doi:10.1111/jpi.12010 · Cited by 829
Self-citationMelatonin as a Potent and Inducible Endogenous Antioxidant: Synthesis and Metabolism
Tan, D.-X., Manchester, L., Esteban-Zubero, E., Zhou, Z., & Reiter, R. (2015) · Molecules · doi:10.3390/molecules201018886 · Cited by 719
“This cascade of reaction with ROS and NOS contributes to its superior protective effects in animal and human studies against oxidative stress [103,104]; this also expands melatonin’s use in industrial fields.”
BackgroundSelf-citation
Metadata
- Authors
- Sanchez-Barcelo, E. J., Mediavilla, M. D., Tan, D. X., & Reiter, R. J.
- Affiliations
- Universidad de Cantabria (ES)
- ORCID
- Reiter, R.J.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-07-01
- Volume
- 17
- Issue
- 19
- Pages
- 2070-2095
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2121858140
- Cited by
- 301
- References
- 0
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 12 · 2023: 12 · 2022: 16 · 2021: 21 · 2020: 24 · 2019: 20 · 2018: 16 · 2017: 27 · 2016: 17 · 2015: 14 · 2014: 23 · 2013: 33 · 2012: 28
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and Work-Related Fatigue
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › melanin and skin pigmentation
- Keywords
- melatonin, clinical efficacy, eye diseases, macular degeneration, glaucoma, gastrointestinal diseases, irritable bowel syndrome, ulcerative colitis, Crohn's disease, rheumatoid arthritis, cardiovascular disease, hypertension, diabetes mellitus, fibromyalgia, chronic fatigue syndrome, infectious diseases, neurological disorders, Alzheimer's disease, Smith-Magenis syndrome, sleep disorders, jet lag, shift work, aging, depression, anesthesia, hemodialysis, in vitro fertilization, neonatal care, adjuvant therapy
- MeSH terms
- Cardiovascular Diseases, Clinical Trials as Topic, Communicable Diseases, Endocrine System Diseases, Eye Diseases, Gastrointestinal Diseases, Hematologic Diseases, Humans, Melatonin, Muscular Diseases, Neoplasms, Nervous System Diseases, Fatigue Syndrome, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review